Trial Profile
A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Indometacin (Primary) ; IRX 2 (Primary) ; Omeprazole (Primary) ; Zinc (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Brooklyn ImmunoTherapeutics; Eterna Therapeutics; IRX Therapeutics
- 11 Sep 2017 Results published in an IRX Therapeutics media release.
- 11 Sep 2017 According to an IRX Therapeutics media release, results from the study have been presented at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
- 02 Aug 2017 According to an IRX Therapeutics media release, data from this trial will be presented at at the European Society for Medical Oncology (ESMO) Annual Congress 2017.